
Opinion|Videos|September 10, 2024
Administering GPRC5D therapy: Dosing and Monitoring for CRS & ICANS
Author(s)Larysa Sanchez, MD, Samantha Shenoy, MSN, NP
Experts explain the administration of step-up and treatment doses for GPRC5D at your institution, including whether they are given in clinic or in the community, and will discuss how patients are monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during the step-up phase.
Advertisement
Episodes in this series

Video content above is prompted by the following:
How are the step-up and treatment doses for GPRC5D administered at your institution? Are they administered in your clinic or in the community?
- How are patients monitored for cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome during step-up dosing?
Advertisement
Related to this article

JoAnne Page, RN, a breast cancer survivor, shares what oncology nurses can do for care partners of patients with bladder cancer.

Giredestrant (Wilserdly) plus everolimus nearly doubled median PFS vs standard endocrine therapy plus everolimus in ESR1-mutated disease in evERA.

Alembic's generic binimetinib, in 15 mg and 45 mg tablets, is therapeutically equivalent to Mektovi for BRAF-mutant melanoma and NSCLC.

The field of oncology continues to evolve, driven by novel drug approvals, innovative delivery technologies, and emerging care strategies in cancer survivorship.

Pertuzumab-qcay is the second FDA-approved biosimilar to Perjeta, but a settlement with Genentech delays its US launch until Q3 2028.

The FDA declined to approve ivonescimab plus chemotherapy after EGFR TKI therapy, citing no statistically significant OS gain in HARMONi.

Cancer care teams are supporting more patients than ever, and oncology teams are navigating the clinical and operational realities that come with that growth.
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Breast Cancer
2
FDA Declines Ivonescimab Approval in EGFR+ NSCLC Over Survival Data
3
FDA Approves Pertuzumab Biosimilar Pebrilzo for HER2+ Breast Cancer
4
FDA Approves Generic Binimetinib for BRAF-Mutant Melanoma and NSCLC
5

